Evidence map›Paper›PMID 34373376›Full record

ArticleInternal medicine (Tokyo, Japan)2022

Intravenous Immunoglobulin in the Treatment of Adalimumab-associated Optic Neuritis.

Naohiro Uchio, Daiki Yashita, Akihito Hao, Toshiyuki Takahashi, Hideyuki Matsumoto

Open access · diamondAbstract readCase Reports
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Naohiro UchioDepartment of Neurology, Mitsui Memorial Hospital, Japan.
Daiki YashitaDepartment of Neurology, Mitsui Memorial Hospital, Japan.
Akihito HaoDepartment of Neurology, Mitsui Memorial Hospital, Japan.
Toshiyuki TakahashiDepartment of Neurology, Tohoku University Graduate School of Medicine, Japan.
Hideyuki MatsumotoDepartment of Neurology, Mitsui Memorial Hospital, Japan.
Mitsui Memorial Hospital · JPNational Hospital Organization · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Optic neuritis (ON) is a rare complication of tumor necrosis factor (TNF)-α inhibitors. The autoantibody serostatus, treatment, and outcome of TNF-α inhibitor-associated ON remain unclear. We herein report a 50-year-old woman with ON following adalimumab therapy. The patient presented with decreasing visual acuity of the right eye, quickly diminishing to light perception. Anti-aquaporin-4 (anti-AQP4) and anti-myelin oligodendrocyte glycoprotein antibodies were negative. Adalimumab was discontinued, and intravenous methylprednisolone and intravenous immunoglobulin (IVIg) were administered. However, her visual acuity improved only up to counting fingers. IVIg may be ineffective depending on the pretreatment severity.

Indexed as

Immunoglobulins, IntravenousOptic NeuritisAdalimumabAquaporin 4AutoantibodiesFemaleHumansMiddle AgedMyelin-Oligodendrocyte GlycoproteinAdalimumabAquaporin 4AutoantibodiesImmunoglobulins, IntravenousMyelin-Oligodendrocyte Glycoproteinadalimumabaquaporin-4intravenous immunoglobulinmyelin oligodendrocyte glycoproteinoptic neuritistumor necrosis factor-α

Identifiers

PMID34373376
PMCPMC8866781
OpenAlexW3187222925

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.